Adial Pharmaceuticals Announces In Vivo Data For Subsidiary Purnovate’s PNV-5032 As A Potential Treatment For Asthma; Says ‘PNV-5032 demonstrated a significant inhibition of pulmonary flow resistance’
CHARLOTTESVILLE, Va., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Purnovate, Inc., a wholly owned subsidiary of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)))) ("Adial" or the "Company"), today
Adial Pharmaceuticals Receives Notice Of Allowance On U.S. Patent For Treatment For Opioid Use Disorder Using AD04
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of
UPDATE: Adial Says In Recent Study ‘PNV-5030 alone exhibited a significant pain reduction as compared to the control group and a similar effect to 1mg/kg morphine.’
PNV-5030 alone exhibited a significant pain reduction as compared to the control group and a similar effect to 1mg/kg morphine. Importantly, PNV-5030 demonstrated a significant effect when administered with 1 mg/kg
Brookline Capital Initiates Coverage On Adial Pharmaceuticals with Buy Rating, Announces Price Target of $12
Brookline Capital analyst Kumaraguru Raja initiates coverage on Adial Pharmaceuticals (NASDAQ:ADIL) with a Buy rating and announces Price Target of $12.
Adial Pharmaceuticals Announces Greater Than 50% Of Patients Expected To Complete ONWARD Phase 3 Trial Of AD04 For Treatment Of Alcohol Use Disorder Have Completed Full 24-Week Treatment Period; Says Trial Completion Anticipated Q1 2022
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of
Adial Pharmaceuticals Announces Research Collaboration Agreement With University Of Virginia To ‘Advance Next Generation Adenosine Compounds for Wound Healing’
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of
The Daily Biotech Pulse: MacroGenics’ Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA’s FDA Nod
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 7)